[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fd4GR1-78C2c_ujikAhrLvhajShWS2P554KoAAujl1Ss":8,"$fpOM_LzFOy5k3XpYSjFghEDzobkrYm9BCb40Jh65apgk":60,"$fIX62UbVlvJXr5SL4kKmpftGnbsuNvrtKDBqrxZAMV7Q":61,"$fjO3ZA9FrLUhxfEKpHFqn0u5L1kYCNm3pW-oRcY0Kh3E":65},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":59},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"roleType":17,"adept":18,"hospital":19,"department":20,"postsTitle":21,"materialTotal":22,"videoTotal":23,"isConcern":7,"title":24,"coverVertical":25,"coverAcross":26,"directionMarker":27,"description":28,"vid":29,"time":30,"mediaType":23,"views":31,"likes":17,"isThumbsUp":7,"isCollection":7,"collections":17,"createTime":32,"seoTitle":33,"seoKeywords":34,"seoDescription":35,"shelvesTime":36,"menus":37,"menuId":39,"type":27,"quality":56,"commentCount":17,"isComment":23,"deviceType":57,"url":58},7318,869766,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//3XpcyZB1zjLvXvcBgd28EEeCWYOBncoP.png","尹慧彬",0,"皮肤性病科常见疾病的诊治，如特应性皮炎","复旦大学附属华山医院","皮肤性病科","主治医师",3,1,"特应性皮炎的靶向治疗药物详解","https://cdn.yishi-tong.com/console/3/0hHgqFq68KxqEyxnkARpPC1EJ8wBH-MW.png","https://cdn.yishi-tong.com/console/3/wIXBd2EcyNoJLXNZxHxDTcgyQmjfNcUj.png",2,"开头：大家好，我是XX医院的XX医生，今天我们重点介绍特应性皮炎（AD）的靶向治疗药物。\n\n内容：\n目前国内已上市的AD靶向药物分属两大类，一类是大分子生物制剂，例如度普利尤单抗注射液、司普奇拜单抗注射液；一类是小分子靶向药，例如乌帕替尼缓释片、阿布昔替尼片、硫酸艾玛昔替尼片。这两类药物有着巨大差异。 \n\n大分子生物制剂通过阻断炎症信号（如IL-4/IL-13）起效，有以下几点缺陷：  \n1. 起效较慢：注射后需经淋巴循环进入血液，达峰时间延迟，通常需4-16周显效；  \n2. 分布局限：分子量大，难以穿透深层组织，主要分布在血液和淋巴中；  \n3. 代谢复杂：可能因免疫反应出现药效波动，如产生抗体降低疗效；  \n4. 安全性注意：极少数可能引发过敏反应，肾功能不全者需谨慎使用； \n5. 给药方式：需定期皮下注射，依从性相对较低。 \n\n小分子靶向药可直接阻断细胞内的炎症通路，相对大分子生物制剂有巨大优势： \n1. 起效迅速：口服后经毛细血管快速吸收，1-2周即可缓解瘙痒；  \n2. 分布广泛：分子量小，可渗透到皮肤深层及全身组织；  \n3. 代谢稳定：剂量与药效呈线性关系，疗效预测性较好；  \n4. 安全性注意：需警惕脱靶效应，如血脂异常、痤疮，但通常不产生免疫原性；  \n5. 给药优势：口服给药，依从性更高。  \n\n那么，应该如何科学选择靶向治疗药物呢？一般来说，求快选口服，求稳选注射。瘙痒难忍、需快速控制的患者选小分子靶向药，倾向于长期控制病情进展的优先选大分子生物制剂。但无论选择哪类药物，都必须坚持基础的日常护理。 \n\n结尾：\n总之，靶向药物在AD治疗方面效果显著，但个体差异巨大，请务必及时就医，切勿自行用药。","v0247cg10004d2v88siljhte3no0kuag",141,527,"2025-06-24 10:41:46","特应性皮炎靶向治疗药物详解：最新药物与治疗方案指南  ","特应性皮炎,靶向治疗,生物制剂,皮炎药物,IL-4抑制剂,IL-13抑制剂,JAK抑制剂,皮炎治疗方案  ","本文详细解析特应性皮炎的靶向治疗药物，包括生物制剂（如达必妥/Dupilumab）和JAK抑制剂的作用机制、疗效及适用人群，帮助患者了解最新治疗选择。","2025-07-08 15:50:02",[38],{"menuId":39,"menuName":40,"parentId":17,"orderNum":22,"path":41,"component":42,"isFrame":43,"isCache":44,"menuType":45,"visible":23,"status":17,"createDept":6,"remark":46,"createTime":47,"children":48,"columnImage":49,"columnLogo":50,"uncheckedLogo":6,"checkedLogo":6,"isHot":17,"isHome":17,"forceLogin":17,"color":6,"seoTitle":51,"seoKeywords":52,"seoDescription":53,"contentNum":6,"promotionalPoster":54,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":55,"routerPath":41,"componentInfo":42},"1986622624134549505","科普视频","video","/video.html","1","0","T","","2025-11-07 10:31:58",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:40/0d7fcb56-3dc4-4dcb-99ca-a5d5c438378e.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:43/958efac7-dd02-4681-b8fd-0dd84b1bbf42.png","健康科普视频大全,了解你的健康生活","健康科普视频, 戒烟视频, 饮食健康视频, 胸痛科普, 用药知识, 职业健康视频, 贫血科普, 眼健康视频","精选健康科普视频,涵盖戒烟、胸痛、饮食、用药与职业健康等多个主题,让你轻松获取科学健康知识,提升生活质量。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:45/fa8fe113-deaa-4454-8105-d629769963dd.png","Video","慢性病,过敏性疾病,皮肤健康",4,"https://vod.haohuanjiao.com/huanjiao/specialistVideo/869766/dad9cfcd-3596-493c-85dc-495d4323e9c1.tmp?a=0&auth_key=1789021062-712e210a3d2c4cee8ddb1d7713843012-0-46e5d855ac96aeceae34122bb3d5beb4&br=914&bt=914&cd=0%7C0%7C0&ch=0&cr=0&cs=0&dr=0&ds=4&eid=v0247cg10004d2v88siljhte3no0kuag&er=0&l=202608110415165D3243FDE8B3CB475548&lr=&mime_type=video_mp4&net=0&pl=0&qs=13&rc=angzcWhrb3Y7NTczNGY3M0ApZG5yNndtbDt5ZzMzajo1eWdeaGwwcWdmNXNhLS1kNC9zc2RyLWtiZWlwNS8xLS5gMS06Yw%3D%3D&vl=&vr=",true,{"code":9,"msg":58,"message":6,"data":6,"success":59},{"code":9,"msg":10,"message":6,"data":62,"success":59},{"pageNo":23,"pageSize":63,"result":64,"totalSize":17},10,[],{"code":9,"msg":10,"message":6,"data":66,"success":59},{"authors":67,"appraiseDimensionScoresVos":68},[],[]]